应用EGFR-TK靶向治疗非小细胞肺癌的临床分析

朱星宇，王惠琴

（陕西省中医药大学第二附属医院呼吸科，陕西 西安，712000）

浏览次数：122次 下载次数：332次

摘要：

目的 分析应用小分子化合物（EGFR-TK）靶向治疗非小细胞肺癌患者的临床效果。方法 回顾性分析我院2015年6月至2016年6月收治的46例非小细胞肺癌患者的临床资料，根据双盲法将其分为研究组与对照组。对照组23例非小细胞肺癌患者给予参一胶囊治疗，研究组23例非小细胞肺癌患者给予EGFR-TK 靶向治疗，对比两组非小细胞肺癌患者的临床治 疗效果和不良反应发生率。结果 与对照组相比，研究组患者的不良反应总发生率、疾病控制率明显更优，差异有统计学意义（P<0.05）。结论 应用EGFR-TK靶向治疗非小细胞肺癌患者的临床效果十分显著，可以在很大程度上改善非小细胞肺癌患者的临床症状，患者耐受性良好，不良反应轻微，值得在临床治疗工作中推广运用。

关键词：EGFR-TK；靶向治疗；非小细胞肺癌

中图分类号：R734.2文献标志码：A文章编号：2096-1413(2017)21-0015-02

Clinical analysis of EGFR-TK targeted therapy on non small cell lung cancer
ZHU Xing-yu, WANG Hui-qin
(Department of Respiratory Medicine, the Second Affiliated Hospital of Shaanxi University of Chinese Medicine,
Xi``an 712000, China)

ABSTRACT: Objective To analyze the clinical effect of small molecule compounds (EGFR-TK) targeted treatment for non-small cell lung cancer patients. Methods The clinical data of 46 patients with non-small cell lung cancer admitted in our hospital from June 2015 to June 2016 were retrospectively analyzed, and the patients were divided into research group (23 cases) and control group (23 cases) according to the double blind method. The control group was given Shenyi capsule treatment, while the research group was given EGFR -TK targeted therapy. Then the clinical therapeutic effect and incidence rate of adverse reactions were compared between the two groups. Results In comparison with the control group, the disease control rate and total incidence rate of adverse reactions of the research group were significantly superior, the differences were statistically significant (P<0.05). Conclusion Application of EGFR-TK targeted therapy  in non-small cell lung cancer is very effective in clinic, it can improve the clinical symptoms of patients with non-small cell lung cancer to a large extent, with good tolerance and mild adverse reactions, which is worthy of promotion in clinical treatment.
KEYWORDS: EGFR-TK; targeted therapy; non small cell lung cancer

参考文献：
[1] 王荣,石冬琴,谢华,等.非小细胞肺癌中EGFR基因突变及靶向药物治疗研究进展[J].中国药理学通报,2013,29(1):22-26.
[2] 陈勇.EGFR 靶向治疗非小细胞肺癌研究进展[J].实用预防医学,2013,20(1):127-128.
[3] 姜北,李晶,万鹏,等.EGFR-TKIs 在晚期非小细胞肺癌靶向治疗中的临床研究[J].现代生物医学进展,2013,13(8):1489-1492.
[4] 袁惠芳.晚期非小细胞肺癌中EGFR 基因突变及靶向药物治疗临床分析[J].中国西部科技,2015,12(6):91-92.
[5] 姜忠于,胡春秀,刘学武,等.靶向药物治疗对表皮生长因子受体基因不同位点突变的非小细胞肺癌患者预后影响[J].中国临床药理学 杂志,2015,31(23):2306-2308.
[6] 魏东.EGFR 基因突变与晚期非小细胞肺癌(NSCLC)的分子靶向治疗[D].石家庄:河北医科大学,2009.